- Pear Therapeutics Inc (NASDAQ:PEAR) announced data that further underscore the effectiveness of Somryst for chronic insomnia at the World Sleep 2022.
- Interim data from the DREAM study, analyzed in mid-Q1 2022, had 991 patients enrolled to date.
- In 779 patients who completed end-of-treatment (EOT), the population achieved statistically significant and clinically meaningful reductions in insomnia severity (ISI), sleep onset latency (SOL), and wake-after-sleep onset (WASO) from baseline to post-treatment at nine weeks.
- In the 193 patients who completed the six-month follow-up, significant improvements in ISI, SOL, and WASO were maintained through six months.
- Interim data showed that of participants treated with Somryst, the mean ISI at baseline was 18.8, and at EOT was found to be 11.3, and at six months 12.1.
- By the end of treatment, 78.7% and 73.3% of participants treated with Somryst achieved the clinically meaningful definition of SOL remission (falling sleeping within 30 minutes or less) and/or WASO remission, respectively.
- Similar patterns in WASO, SOL, sleep efficiency and sleep quality were also demonstrated in an additional study evaluating older adults (55 years of age or older).
- Somryst is an FDA-authorized 9-week prescription digital therapeutic (PDT) that addresses the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia.
- Price Action: PEAR shares are up 10.30% at $4.61 during the market session on the last check Tuesday.
